Find Clinical Trial

Home » Find Clinical Trials » Evaluation of the effect of the oral administration of perindopril orodispersible at a dose of 0.150 mg/kg/day on the muscular and myocardial function in early stage Duchenne muscular dystrophy. Double blind two years study, randomised versus placebo

Evaluation of the effect of the oral administration of perindopril orodispersible at a dose of 0.150 mg/kg/day on the muscular and myocardial function in early stage Duchenne muscular dystrophy. Double blind two years study, randomised versus placebo

← Back

Study Phase	Phase 3

Therapeutic Area	Cardiovascular Diseases

Indication	Muscular disease

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	PERINDOPRIL ARGININE, S090652

Active Substance Code	S090652

Protocol Code	CL3-90652-004

EudraCT Code	2008-003856-32

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.